Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia
Open accessAbstract
Schizophrenia is a serious mental disorder requiring lifelong treatment. While medications are available that are effective in treating some patients, individual treatment responses can vary, with some patients exhibiting resistance to one or multiple drugs. Currently, little is known about the causes of the difference in treatment response observed among individuals with schizophrenia, and satisfactory markers of poor response are not available for clinical practice. Here, we studied the changes in the levels of 322 blood plasma lipids between two time points assessed in 92 individuals diagnosed with schizophrenia during their inpatient treatment and their association with the extent of symptom improvement. We found 20 triglyceride species increased in individuals with the least improvement in Positive and Negative Syndrome Scale (PANSS) scores, but not in those with the largest reduction in PANSS scores. These triglyceride species were distinct from the rest of the triglyceride species present in blood plasma. They contained a relatively low number of carbons in their fatty acid residues and were relatively low in abundance compared to the principal triglyceride species of blood plasma.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Nine studies evaluated broad panels of different lipid markers in patients with SCZ and detected statistical differences in fatty acyls, sterols, glycerolipids, sphingolipids, glycerophospholipids, and products of lipid metabolism.
“Nine studies evaluated the broad panels of different lipid markers in patients with SCZ [31,34,40,41,42,43,44,45,46] and detected statistical differences in the following lipid classes: fatty acyls, sterols, glycerolipids, sphingolipids, glycerophospholipids, and products of lipid metabolism.”
From Lipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers (2024) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.
Kay, S. R., Fiszbein, A., & Opler, L. A. (1987) · Schizophrenia Bulletin · doi:10.1093/schbul/13.2.261 · Cited by 21,378 · cited 2× · see citing works
“by Positive and Negative Syndrome Scale (PANSS) [34] score at the two time points (Table S1).”
Smith, C. A., Want, E. J., O’Maille, G., Abagyan, R. A., & Siuzdak, G. E. (2006) · Analytical Chemistry · doi:10.1021/ac051437y · Cited by 5,296 · cited 1× · see citing works
“Spectra were processed using XCMS software [35], using the “centWave” method for peak detection, the “obiwarp” method for retention time correction, and the “fill-Peaks” method for missing value imputation.”
MethodThe emerging field of lipidomics
Wenk, M. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1776 · Cited by 1,325 · cited 1× · see citing works
“In part, this can be attributed to the fast-developing field of lipid research [4,5].”
BackgroundMitchell, A. J., Vancampfort, D., Sweers, K., van Winkel, R., Yu, W., & Binder, M. D. (2011) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr148 · Cited by 1,087 · see citing works
De Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., Holt, R. I. G., & Möller, H.-J. (2009) · European Psychiatry · doi:10.1016/j.eurpsy.2009.01.005 · Cited by 951 · see citing works
Rhee, E. P., Cheng, S., Larson, M. G., Walford, G. A., Lewis, G. D., McCabe, E., Yang, E., Farrell, L., Fox, C. S., O’Donnell, C. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44442 · Cited by 647 · cited 1× · see citing works
“In general, short-chain triglycerides, in particular, have been found to be associated with diabetes and nonalcoholic fatty liver disease [41,42].”
BackgroundMetabolic syndrome in psychiatric patients: overview, mechanisms, and implications
Penninx, B. W. J. H., & Lange, S. M. M. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/bpenninx · Cited by 566 · see citing works
The effects of antipsychotic therapy on serum lipids: a comprehensive review
Meyer, J. M., & Koro, C. E. (2004) · Schizophrenia Research · doi:10.1016/j.schres.2004.01.014 · Cited by 407 · cited 1× · see citing works
“Antipsychotic treatment has previously been shown to affect both clinical lipid measurements, such as total triglycerides, and compounds at the level of lipid species [12,25,32,43,44].”
A neuroscientist's guide to lipidomics
Piomelli, D., Astarita, G., & Rapaka, R. S. (2007) · Nature reviews. Neuroscience · doi:10.1038/nrn2233 · Cited by 380 · cited 1× · see citing works
“There is also a growing awareness of the important function lipids are now known to play in both the properties and functionality of the brain, such as membrane fluidity and permeability, retrograde signaling, neural plasticity, and neurotransmitter release modulation [6,7].”
BackgroundPotkin, S. G., Kane, J. M., Correll, C. U., Lindenmayer, J.-P., Agid, O., Marder, S. R., Olfson, M., & Howes, O. D. (2020) · npj Schizophrenia · doi:10.1038/s41537-019-0090-z · Cited by 359 · cited 1× · see citing works
“While antipsychotics, among other possible additional treatments, are typically used as medication aimed to reduce symptoms of schizophrenia, treatment efficacy varies between individuals [1], and it is estimated that up to 34% of SCZ patients exhibit resistance to two or more antipsychotic medications [2].”
Szymanski, S., Lieberman, J. A., Alvir, J. M., Mayerhoff, D. I., Loebel, A., Geisler, S., Chakos, M., Koreen, A., Jody, D. N., & Kane, J. M. (1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.5.698 · Cited by 319 · cited 2× · see citing works
“Symptom improvement after antipsychotic treatment was shown to be sex-dependent in this study (Figure S7) as well as others [37,38].”
Burla, B., Arita, M., Arita, M., Bendt, A. K., Cazenave‐Gassiot, A., Dennis, E. A., Ekroos, K., Han, X., Ikeda, K., Liebisch, G., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.s087163 · Cited by 314 · cited 1× · see citing works
“Assessed lipid species covered 14 lipid classes and aligned well with expected blood plasma lipidome composition [36] (Figure S2).”
BackgroundSartorius, N. (2018) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2018.20.1/nsartorius · Cited by 292 · see citing works
Membrane Lipids in Presynaptic Function and Disease.
Lauwers, E., Goodchild, R. E., & Verstreken, P. (2016) · Neuron · doi:10.1016/j.neuron.2016.02.033 · Cited by 213 · cited 1× · see citing works
“There is also a growing awareness of the important function lipids are now known to play in both the properties and functionality of the brain, such as membrane fluidity and permeability, retrograde signaling, neural plasticity, and neurotransmitter release modulation [6,7].”
Liu, X., Zheng, P., Zhao, X., Zhang, Y., Hu, C., Li, J., Zhao, J., Zhou, J., Xie, P., & Xu, G. (2015) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5b00144 · Cited by 193 · see citing works
Zhang, J., Lencz, T., Zhang, R. X., Nitta, M., Maayan, L. A., John, M., Robinson, D. G., Fleischhacker, W. W., Kahn, R. S., Ophoff, R. A., et al. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw058 · Cited by 182 · see citing works
Schizophrenia shows a unique metabolomics signature in plasma
He, Y., Yu, Z., Giegling, I., Xie, L., Hartmann, A. M., Prehn, C. P., Adamski, J., Kahn, R. S., Li, Y., Illig, T., et al. (2012) · Translational Psychiatry · doi:10.1038/tp.2012.76 · Cited by 170 · see citing works
Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids
Orešič, M., Hyötyläinen, T., Kotronen, A., Gopalacharyulu, P. V., Nygrén, H., Arola, J. T., Castillo, S., Mattila, I. M., Hakkarainen, A., Borra, R., et al. (2013) · Diabetologia · doi:10.1007/s00125-013-2981-2 · Cited by 168 · cited 1× · see citing works
“In general, short-chain triglycerides, in particular, have been found to be associated with diabetes and nonalcoholic fatty liver disease [41,42].”
BackgroundDemirkan, A., Isaacs, A., Ugocsai, P., Liebisch, G., Struchalin, M., Rudan, I., Wilson, J. F., Pramstaller, P. P., Gyllensten, U., Campbell, H., et al. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.11.001 · Cited by 163 · see citing works
Beyene, H. B., Olshansky, G., Smith, A., Giles, C., Huynh, K., Cinel, M. A., Mellett, N. A., Cadby, G., Hung, J., Hui, J., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000870 · Cited by 161 · cited 3× · see citing works
“Like others [30], we have found that both sex and age have a strong effect on lipid abundances (number of significant lipids n = 41 and n = 36 for sex and age, respectively; ANOVA, Benjamini– Hochberg correction FDR 5%; Figure S11A; Table S2).”
Plasma lipidomics reveals potential lipid markers of major depressive disorder
Liu, X., Li, J., Zheng, P., Zhao, X., Zhou, C., Hu, C., Hou, X., Wang, H., Xie, P., & Xu, G. (2016) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9768-5 · Cited by 148 · see citing works
Targeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder
Brunkhorst-Kanaan, N., Klatt‐Schreiner, K., Hackel, J., Schröter, K., Trautmann, S., Hahnefeld, L., Wicker, S., Reif, A., Thomas, D., Geißlinger, G., et al. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.002 · Cited by 132 · see citing works
Zhang, X. Y., Chen, D. C., Xiu, M. H., Yang, F. D., Haile, C. N., Kosten, T. A., & Kosten, T. R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07422 · Cited by 117 · cited 2× · see citing works
“Symptom improvement after antipsychotic treatment was shown to be sex-dependent in this study (Figure S7) as well as others [37,38].”
ResultTessier, C., Sweers, K., Frajerman, A., Bergaoui, H., Ferreri, F., Delva, C., Lapidus, N., Lamazière, A., Roiser, J. P., Hert, M. A. F. D., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.142 · Cited by 101 · see citing works
Lipidomics: Current state of the art in a fast moving field
O’Donnell, V. B., Ekroos, K., Liebisch, G., & Wakelam, M. J. O. (2019) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1466 · Cited by 97 · cited 1× · see citing works
“In part, this can be attributed to the fast-developing field of lipid research [4,5].”
BackgroundElevated Plasma Ceramides in Depression
Gracia‐García, P., Rao, V., Haughey, N. J., Bandaru, V. V. R., Smith, G. S., Rosenberg, P. B., Lobo, A., Lyketsos, C. G., & Mielke, M. M. (2011) · Journal of Neuropsychiatry · doi:10.1176/jnp.23.2.jnp215 · Cited by 96 · see citing works
Fond, G. B., d’Albis, M.-A., Jamain, S., Tamouza, R., Arango, C., Fleischhacker, W. W., Glenthoj, B. Y., Leweke, F. M., Lewis, S. W., McGuire, P. K., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv002 · Cited by 96 · cited 1× · see citing works
“Satisfactory biomarkers of treatment response and treatment resistance in schizophrenia would be extremely valuable, but are yet to be discovered [3].”
Ceramides and depression: A systematic review
Dinoff, A., Herrmann, N., & Lanctôt, K. L. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.02.008 · Cited by 95 · cited 1× · see citing works
“Additionally, ceramides have been proposed as a potential biomarker of depression [28].”
BackgroundImpaired Plasmalogens in Patients with Schizophrenia
Kaddurah-Daouk, R., McEvoy, J., Baillie, R., Zhu, H., K. Yao, J., Nimgaonkar, V. L., Buckley, P. F., Keshavan, M. S., Georgiades, A., & Nasrallah, H. A. (2012) · Psychiatry Research · doi:10.1016/j.psychres.2012.02.019 · Cited by 89 · see citing works
The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis
McCutcheon, R. A., Pillinger, T., Mizuno, Y., Montgomery, A., Pandian, H., Vano, L. J., Marques, T. R., & Howes, O. D. (2019) · Molecular Psychiatry · doi:10.1038/s41380-019-0502-5 · Cited by 88 · cited 1× · see citing works
“While antipsychotics, among other possible additional treatments, are typically used as medication aimed to reduce symptoms of schizophrenia, treatment efficacy varies between individuals [1], and it is estimated that up to 34% of SCZ patients exhibit resistance to two or more antipsychotic medications [2].”
BackgroundCao, B., Wang, D., Pan, Z., Brietzke, E. M., McIntyre, R. S., Musial, N., Mansur, R. B., Subramanieapillai, M., Zeng, J., Huang, N., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-018-0353-x · Cited by 82 · cited 1× · see citing works
“Among other lipid compounds, the lipid classes most robustly associated with the disorder are ether phospholipids (such as plasmanyl-/plasmenyl- phosphatidylcholine and plasmanyl/plasmenyl- phosphatidylethanolamine) [9,11–14,24] and acylcarnitines [8,10,15,25,26].”
Metabolic Profiling Identifies Phospholipids as Potential Serum Biomarkers for Schizophrenia
Wang, D., Cheng, S. L., Fei, Q., Gu, H., Raftery, D., Cao, B., Sun, X., Yan, J., Zhang, C., & Wang, J. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2018.12.008 · Cited by 73 · see citing works
Profiling of Lipidomics Before and After Antipsychotic Treatment in First-Episode Psychosis
Leppik, L., Parksepp, M., Janno, S., Koido, K., Haring, L., Vasar, E., & Zilmer, M. (2018) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-018-0971-6 · Cited by 55 · see citing works
Wong, M. W. K., Braidy, N., Pickford, R., Vafaee, F., Crawford, J. D., Muenchhoff, J., Schofield, P. W., Attia, J., Brodaty, H., Sachdev, P. S., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0214141 · Cited by 51 · cited 1× · see citing works
“While blood lipid alterations have been shown for psychiatric disorders, their levels are subject to a degree of variability related to sex, age, metabolic health, and, possibly, other unaccounted factors [29,30].”
Dysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia
Wood, P. L., Unfried, G., Whitehead, W. F., Phillipps, A., & Wood, J. A. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.11.032 · Cited by 50 · see citing works
Kim, E. Y., Lee, J. W., Lee, M. Y., Kim, S. H., Mok, H. J., Ha, K., Ahn, Y. M., & Kim, K. P. (2018) · Psychiatry Research · doi:10.1016/j.psychres.2018.04.029 · Cited by 50 · see citing works
Profiling of Acylcarnitines in First Episode Psychosis before and after Antipsychotic Treatment
Kriisa, K., Leppik, L., Balõtšev, R., Ottas, A., Soomets, U., Koido, K., Volke, V., Innos, J., Haring, L., Vasar, E., et al. (2017) · Journal of Proteome Research · doi:10.1021/acs.jproteome.7b00279 · Cited by 47 · cited 1× · see citing works
“Among other lipid compounds, the lipid classes most robustly associated with the disorder are ether phospholipids (such as plasmanyl-/plasmenyl- phosphatidylcholine and plasmanyl/plasmenyl- phosphatidylethanolamine) [9,11–14,24] and acylcarnitines [8,10,15,25,26].”
Association between Serum Lipids and Antipsychotic Response in Schizophrenia
Kim, D. D., Barr, A. M., Fredrikson, D. H., Honer, W. G., & Procyshyn, R. M. (2019) · Current Neuropharmacology · doi:10.2174/1570159x17666190228113348 · Cited by 46 · cited 2× · see citing works
“This effect, however, was not reproduced by others [39].”
Knowles, E. E. M., Huynh, K., Meikle, P. J., Göring, H. H. H., Olvera, R. L., Mathias, S. R., Duggirala, R., Almasy, L. A., Blangero, J., Curran, J. E., et al. (2017) · European Psychiatry · doi:10.1016/j.eurpsy.2017.02.479 · Cited by 43 · see citing works
Li, R., Zhang, Y., Zhu, W., Ding, C., Dai, W., Su, X., Dai, W., Xiao, J., Xing, Z., & Huang, X. (2020) · Scientific Reports · doi:10.1038/s41598-020-73983-4 · Cited by 43 · cited 1× · see citing works
“Antipsychotic treatment has previously been shown to affect both clinical lipid measurements, such as total triglycerides, and compounds at the level of lipid species [12,25,32,43,44].”
Backgroundde Almeida, V., Alexandrino, G. L., Aquino, A., Gomes, A. F., Murgu, M., Dobrowolny, H., Guest, P. C., Steiner, J., & Martins-de-Souza, D. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109945 · Cited by 39 · cited 1× · see citing works
“Antipsychotic treatment has previously been shown to affect both clinical lipid measurements, such as total triglycerides, and compounds at the level of lipid species [12,25,32,43,44].”
Suvitaival, T., Mantere, O., Kieseppä, T., Mattila, I. M., Pöhö, P., Hyötyläinen, T., Suvisaari, J., & Orešič, M. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.222 · Cited by 38 · cited 1× · see citing works
“Interestingly, one study has found that an increase in triglycerides with these chain length ranges was associated with weight gain in first psychotic episode patients after undergoing treatment [40].”
BackgroundCao, B., Jin, M., Brietzke, E. M., McIntyre, R. S., Wang, D., Rosenblat, J. D., Ragguett, R., Zhang, C., Sun, X., Rong, C., et al. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12779 · Cited by 37 · cited 2× · see citing works
“Antipsychotic treatment has previously been shown to affect both clinical lipid measurements, such as total triglycerides, and compounds at the level of lipid species [12,25,32,43,44].”
BackgroundYan, L., Zhou, J., Wang, D., Si, D., Liu, Y., Zhong, L., & Yin, Y. (2018) · Metabolomics · doi:10.1007/s11306-018-1375-3 · Cited by 36 · cited 1× · see citing works
“Antipsychotic treatment has previously been shown to affect both clinical lipid measurements, such as total triglycerides, and compounds at the level of lipid species [12,25,32,43,44].”
Chen, Y., Chen, K., Chiu, C., Tai, M., & Lung, F. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1950-1 · Cited by 26 · see citing works
Cao, B., Wang, D., Pan, Z., McIntyre, R. S., Brietzke, E. M., Subramanieapillai, M., Nozari, Y., & Wang, J. (2019) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2019.1615639 · Cited by 26 · cited 1× · see citing works
“Among other lipid compounds, the lipid classes most robustly associated with the disorder are ether phospholipids (such as plasmanyl-/plasmenyl- phosphatidylcholine and plasmanyl/plasmenyl- phosphatidylethanolamine) [9,11–14,24] and acylcarnitines [8,10,15,25,26].”
BackgroundWang, D., Sun, X., Maziade, M., Mao, W., Zhang, C., Wang, J., & Cao, B. (2021) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2020.1769188 · Cited by 26 · see citing works
Beyene, H. B., Olshansky, G., Smith, A., Giles, C., Huynh, K., Cinel, M. A., Mellett, N. A., Cadby, G., Hung, J., Hui, J., et al. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3001049 · Cited by 23 · see citing works
Cuturic, M., Abramson, R. K., Breen, R., Edwards, A. C., & Levy, E. E. (2016) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2016.1178803 · Cited by 19 · cited 1× · see citing works
“Among other lipid compounds, the lipid classes most robustly associated with the disorder are ether phospholipids (such as plasmanyl-/plasmenyl- phosphatidylcholine and plasmanyl/plasmenyl- phosphatidylethanolamine) [9,11–14,24] and acylcarnitines [8,10,15,25,26].”
BackgroundCai, H., Cao, T., Li, N., Fang, P., Xu, P., Wu, X., Zhang, B., & Xiang, D. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01956-2 · Cited by 18 · see citing works
Brown, F. W. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11bk06921 · Cited by 5 · see citing works
T45. THE EFFICACY AND HETEROGENEITY OF ANTIPSYCHOTIC RESPONSE IN SCHIZOPHRENIA: A META-ANALYSIS
McCutcheon, R., Pillinger, T., Mizuno, Y., Montgomery, A., Pandian, H., Vano, L. J., Marques, T. R., & Howes, O. D. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa029.605 · Cited by 2 · see citing works
Hert, D., Dekker, J. J. M., Wood, D. V., Kahl, K. G., Holt, R. J., & Moller, H. J. (2009) · Data Archiving and Networked Services (DANS) · Cited by 1 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Tkachev, A., Stekolshchikova, E., Vanyushkina, A., Zhang, H., Morozova, A. Y., Zozulya, S. A., Kurochkin, I., Anikanov, N. A., Egorova, A., Yushina, E., et al. (2023) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.4350 · Cited by 78 · see citing works
Self-citationLipids in Psychiatric Disorders: Functional and Potential Diagnostic Role as Blood Biomarkers
Zorkina, Y., Ushakova, V., Ochneva, A., Tsurina, A., Abramova, O., Savenkova, V., Goncharova, A., Alekseenko, I., Morozova, I., Riabinina, D., et al. (2024) · Metabolites · doi:10.3390/metabo14020080 · Cited by 36 · see citing works
“For example, such correlations have been detected for shorter-chain TGs [41] and oxysterols [55].”
BackgroundMetabolomics, Lipidomics, and Antipsychotics: A Systematic Review
Burghardt, K. J., Kajy, M., Ward, K. M., & Burghardt, P. R. (2023) · Biomedicines · doi:10.3390/biomedicines11123295 · Cited by 16 · see citing works
“Three studies included analyses of metabolites associated with antipsychotic response [9,17,42].”
BackgroundScreening for depression in the general population through lipid biomarkers
Tkachev, A., Stekolshchikova, E., Golubova, A., Serkina, A., Morozova, A. Y., Zorkina, Y., Riabinina, D., Golubeva, E., Ochneva, A., Savenkova, V., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105455 · Cited by 15 · see citing works
Self-citationCeramides: Shared Lipid Biomarkers of Cardiovascular Disease and Schizophrenia
Tkachev, A., Stekolshchikova, E., Morozova, A. Y., Anikanov, N. A., Zorkina, Y., Alekseyeva, P. N., Khobta, E. B., Andreyuk, D., Zozulya, S. A., Barkhatova, A., et al. (2021) · Consortium Psychiatricum · doi:10.17816/cp101 · Cited by 8 · see citing works
Self-citationKohshour, M. O., Papiol, S., Tkachev, A., Stekolshchikova, E., Adorjan, K., Budde, M., Heilbronner, U., Heilbronner, M., Kalman, J., Reich-Erkelenz, D., et al. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03323-5 · Cited by 4 · see citing works
“After excluding all lipid species known to be altered by fasting status ( n = 30; of which 26 were fatty acids) [51], 364 annotated lipids species not affected by fasting status remained and were carried forward to the analysis (Supplementary tables S1 – S3).”
Self-citationPlasma and Serum LC-MS Lipidomic Fingerprints of Bipolar Disorder and Schizophrenia
Takić, M. M., Jovanović, V. B., Marković, S., Miladinović, Z. P., Jadranin, M. B., Krstić, G., Miljević, Č., Tešević, V., & Mandić, B. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136134 · Cited by 4 · see citing works
“The treatment with antipsychotics could additionally affect TG concentrations [126–128], and serum/plasma TG profiles.”
LC–HRMS Lipidomic Fingerprints in Serbian Cohort of Schizophrenia Patients
Marković, S., Jadranin, M. B., Miladinović, Z. P., Gavrilović, A., Avramović, N., Takić, M. M., Tasić, L., Tešević, V., & Mandić, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251910266 · Cited by 4 · see citing works
“Tkachev et al. (2021) determined the abundance of Cer(d18:1/16:0), Cer(d18:1/18:0) and Cer(d18:1/24:1) in the plasma of 82 SCH patients and 138 controls using LC–HRMS and confirmed a higher content of all three types of Cer in patients with SCH compared to control groups, which is in agreement with…”
ResultDiscrimination of Bipolar Disorder and Schizophrenia Patients Based on LC-HRMS Lipidomics
Janković, M. R., Avramović, N., Miladinović, Z., Jadranin, M. B., Takić, M. M., Krstić, G., Gavrilović, A., Miljević, Č., Pantović, M., Andrić, Z., et al. (2026) · Metabolites · doi:10.3390/metabo16010069 · Cited by 2 · see citing works
“Several recent lipidomics studies suggest that antipsychotic treatments in SCH patients could lead to the alteration of serum lipid profiles, including the downregulation of shorter-chain triacylglycerols [21,33,34].”
Li, Y., Wang, G., Fang, X., Ling, Y., Zhou, C., Fang, J., Cai, R., Hu, Y., Wu, C., Zhang, S., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106235
Weber, A., Papiol, S., Tkachev, A., Senner, F., Reich‐Erkelenz, D., Navarro‐Flores, A., Kohshour, M. O., Heilbronner, U., Heilbronner, M., Budde, M., et al. (2026) · medRxiv · doi:10.64898/2026.01.06.26343451
Self-citation
- Authors
- Tkachev, A., Stekolshchikova, E., Anikanov, N., Zozulya, S., Barkhatova, A., Klyushnik, T., & Petrova, D.
- Affiliations
- Skolkovo Institute of Science and Technology (RU)
- V. Zelman Center for Neurobiology and Brain Restoration, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia
- Mental Health Research Center of Russian Academy of Medical Sciences (RU)
- Corresponding author
- Tkachev, Anna
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-05-11
- Volume
- 11
- Issue
- 5
- Pages
- 720
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC8151512
- OpenAlex
- W3163838196
- Cited by
- 11
- References
- 53
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 3 · 2023: 2 · 2021: 1
- FWCI
- 1.08
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Russian Science Foundation (19-74-00151)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Keywords
- schizophrenia, triglycerides, short-chain fatty acids, plasma lipids, treatment response, symptom improvement, PANSS, lipidomics, biomarkers, inpatient care
- MeSH terms
- Lipidomics, Adolescent, Adult, Behavioral Symptoms, Female, Humans, Inpatients, Male, Russia, Schizophrenia, Antipsychotic Agents, Triglycerides, Biomarkers, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
